GGrantIndex
← Leaderboards

Michael Oscar Harhay

University Of Pennsylvania

$3,671,438
Attributed
$6,522,481
Total exposure
7
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.8M · FY201525
$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,522,481 · 7

By mechanism

R01$4,346,082 · 3
U01$1,144,421 · 1
R00$747,000 · 1
K99$213,755 · 1
F31$71,223 · 1

Top collaborators

Most similar at University Of Pennsylvania

Same institution · by research overlap

Others in their field

Top investigators on “Survivors

Research focus

SurvivorsCognitiveInnovationMorbidity - Disease RateQuality Of LifeEpidemiologyDesignFutureMortalityNational Heart, Lung, And Blood InstituteMethodologyEnrollmentPrognosticReportingIntensive Care UnitsResearch PersonnelFundingCessation Of LifeCaringPatient-Focused OutcomesHeterogeneityCohortClinical DataCommunities

Grant awards (16)

Pediatric Acute Respiratory distress syndrome MAnagement (PARMA)$767,069
R01 · FY2025 · HD
Advancing the design, analysis, and interpretation of acute respiratory distress syndrome trials using modern statistical tools$726,564
R01 · FY2025 · HL · contact PI
Improving the delivery and equity of inpatient palliative care: a hybrid type I pragmatic cluster trial$664,696
R01 · FY2025 · AG
Phenotyping ARDS, Pneumonia, and Sepsis over time to elucidate shared and distinct trajectories ofillness and recovery$634,751
U01 · FY2025 · HL
Advancing the design, analysis, and interpretation of acute respiratory distress syndrome trials using modern statistical tools$717,154
R01 · FY2024 · HL · contact PI
Improving the delivery and equity of inpatient palliative care: a hybrid type I pragmatic cluster trial$690,884
R01 · FY2024 · AG
Phenotyping ARDS, Pneumonia, and Sepsis over time to elucidate shared and distinct trajectories ofillness and recovery$350,420
U01 · FY2024 · HL
Advancing the design, analysis, and interpretation of acute respiratory distress syndrome trials using modern statistical tools$779,715
R01 · FY2023 · HL · contact PI
Phenotyping ARDS, Pneumonia, and Sepsis over time to elucidate shared and distinct trajectories ofillness and recovery$159,250
U01 · FY2023 · HL
Improving the measurement and analysis of long-term, patient-centered outcomes following acute respiratory failure$249,000
R00 · FY2022 · HL · contact PI
Improving the measurement and analysis of long-term, patient-centered outcomes following acute respiratory failure$249,000
R00 · FY2021 · HL · contact PI
Improving the measurement and analysis of long-term, patient-centered outcomes following acute respiratory failure$249,000
R00 · FY2020 · HL · contact PI
Improving the measurement and analysis of long-term, patient-centered outcomes following acute respiratory failure$108,012
K99 · FY2019 · HL · contact PI
Improving the measurement and analysis of long-term, patient-centered outcomes following acute respiratory failure$105,743
K99 · FY2018 · HL · contact PI
Methods to improve the detection of treatment effects in ARDS clinical trials$28,103
F31 · FY2016 · HL · contact PI
Methods to improve the detection of treatment effects in ARDS clinical trials$43,120
F31 · FY2015 · HL · contact PI